<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="./datadict_v2.xsl"?><data_table id="pht003996.v1" study_id="phs000772.v1" participant_set="1" date_created="Thu Aug 21 10:23:55 2014"><description>Subject ID, ethnicity, erectile dysfunction, prostatic rectal bleeding, AUASS score before and after radiotherapy, prostate resection, age at time of radiotherapy, radiotherapy type, anti-androgen therapy, prostate tumor stage, Gleason score, PSA, CT scan, radiation dose, smoking, diabetes, and  hypertension status, and use of alpha-blocker drugs among participants with or without prostate cancer and involved in the "Genetic Predictors of Adverse Radiotherapy Effects (Gene-PARE)" project.</description><variable id="phv00202671.v1"><name>SUBJECT_ID</name><description>De-identified subject ID</description><type>string</type></variable><variable id="phv00202672.v1"><name>ED</name><description>Erectile dysfunction</description><type>encoded value</type><value code="0">Control</value><value code="1">Case</value></variable><variable id="phv00202673.v1"><name>proctitis</name><description>Proctitis/rectal bleeding</description><type>encoded value</type><value code="0">Control</value><value code="1">Case</value></variable><variable id="phv00202674.v1"><name>IPSS.delta.y1</name><description>Change in AUASS score from baseline recorded between 1 and 2 years following radiotherapy</description><type>integer</type><logical_min>0</logical_min><logical_max>35</logical_max></variable><variable id="phv00202675.v1"><name>IPSS.delta.y2</name><description>Change in AUASS score from baseline recorded between 2 and 3 years following radiotherapy</description><type>integer</type><logical_min>0</logical_min><logical_max>35</logical_max></variable><variable id="phv00202676.v1"><name>IPSS.delta.y3</name><description>Change in AUASS score from baseline recorded between 3 and 4 years following radiotherapy</description><type>integer</type><logical_min>0</logical_min><logical_max>35</logical_max></variable><variable id="phv00202677.v1"><name>IPSS.delta.y4</name><description>Change in AUASS score from baseline recorded between 4 and 5 years following radiotherapy</description><type>integer</type><logical_min>0</logical_min><logical_max>35</logical_max></variable><variable id="phv00202678.v1"><name>race</name><description>Self-reported race/ethnicity of participant [Black, Asian, Caucasian, Hispanic]</description><type>string</type></variable><variable id="phv00202679.v1"><name>prior.TURP</name><description>Transurethral resection of the prostate prior to radiotherapy</description><type>encoded value</type><value code="0">No</value><value code="1">Yes</value></variable><variable id="phv00202680.v1"><name>PreRT.AUASS</name><description>Pre-radiotherapy AUASS score</description><type>integer</type><logical_min>0</logical_min><logical_max>35</logical_max></variable><variable id="phv00202681.v1"><name>age.at.Rx</name><description>Subject age at time of radiotherapy</description><type>integer</type><unit>Years</unit><logical_min>43</logical_min><logical_max>85</logical_max></variable><variable id="phv00202682.v1"><name>hormones</name><description>Anti-androgen therapy given before, during and/or after radiotherapy</description><type>encoded value</type><value code="0">No</value><value code="1">Yes</value></variable><variable id="phv00202683.v1"><name>treatment</name><description>Radiotherapy type (external beam radiotherapy, EBRT; brachytherapy) [EBRT, Brachytherapy, EBRT and Brachytherapy]</description><type>string</type></variable><variable id="phv00202684.v1"><name>stage</name><description>Prostate tumor stage [T1a, T1b, T1c, T2a, T2b, T2c, T3a, T3b, T3c, Recurrence]</description><type>string</type></variable><variable id="phv00202685.v1"><name>gleason.score</name><description>Gleason score of prostate tumor</description><type>integer</type><logical_min>3</logical_min><logical_max>10</logical_max></variable><variable id="phv00202686.v1"><name>initial.PSA</name><description>Blood concentration of prostate specific antigen (PSA)</description><type>numeric</type><unit>ng/ml</unit><logical_min>0.55</logical_min><logical_max>300</logical_max></variable><variable id="phv00202687.v1"><name>prostatectomy</name><description>Radical prostatectomy prior to radiotherapy</description><type>encoded value</type><value code="0">No</value><value code="1">Yes</value></variable><variable id="phv00202688.v1"><name>CT.Volume</name><description>Prostate volume on CT scan prior to radiotherapy</description><type>numeric</type><unit>cm3</unit><logical_min>17.24</logical_min><logical_max>187</logical_max></variable><variable id="phv00202689.v1"><name>Total.BED</name><description>Total biologically effective dose, combining EBRT and implant dose when both treatments were used, calculated using an</description><type>numeric</type><logical_min>52.43</logical_min><logical_max>320</logical_max></variable><variable id="phv00202690.v1"><name>EBRT.Dose</name><description>Radiation dose delivered from external beam radiotherapy</description><type/></variable><variable id="phv00202691.v1"><name>smoker</name><description>Smoking status at the time of radiotherapy</description><type>encoded value</type><value code="0">No</value><value code="1">Yes</value></variable><variable id="phv00202692.v1"><name>diabetes</name><description>Diabetes status at the time of radiotherapy</description><type>encoded value</type><value code="0">No</value><value code="1">Yes</value></variable><variable id="phv00202693.v1"><name>hypertension</name><description>Hypertension status at the time of radiotherapy</description><type>encoded value</type><value code="0">No</value><value code="1">Yes</value></variable><variable id="phv00202694.v1"><name>alpha.blockers</name><description>Use of alpha-blocker drugs during treatment or follow-up</description><type>encoded value</type><value code="0">No</value><value code="1">Yes</value></variable></data_table>
